Rapport
The switch from ROTARIX to ROTAVAC in Ghana: Answers to four key questions
In 2020, Ghana's switched from ROTARIX to ROTAVAC in its routine immunization program in order to save money and cold chain space. An economic analysis of this switch, conducted by PATH, the University of Ghana, and Ghana Health Service, found that the switch was indeed cost-saving for Ghana. The results may be of interest to other countries considering similar rotavirus vaccine product switches.
In 2020, Ghana switched from using ROTARIX® to ROTAVAC® in its national immunization program. PATH worked with Ghana Health Service and the University of Ghana to analyze the economic implications of this switch. These four fact sheets explore the key results of these analyses, collectively providing a case study on Ghana’s rotavirus vaccine product switch.
(Manuscript pending submission to a peer-reviewed journal.)
Corporate author(s): PATH
Publication date: May 2022
Auteurs
Langues
- Anglais
Année de publication
2022
Type
Rapport
Catégories
- Gestion de programme
Maladies
- Rotavirus
Pays
- Ghana
Organisations
- PATH
Mots-clés
- Planification, budgétisation et financement
- Politique et législation
Régions de l'OMS
- Région africaine
PORTFOLIO-LESSONS
Vous pouvez trouver plus d’informations sur "PORTFOLIO-LESSONS" dans les rubriques suivantes :
| Titre | Auteur | Année | Type | Langue |
|---|---|---|---|---|
| The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia | Kirstin Krudwig, Barbara Knittel, Ali Karim, Natasha Kanagat, Wendy Prosser, Guissimon Phiri, Frances Mwansa, Robert Steinglass | 2020 | Journal article | Anglais |
| A Switch for Sustainability in Ghana's Rotavirus Vaccine Program | George Armah | 2020 | Case study | Anglais |
| Introducing 5-dose Measles-Rubella Vaccine Vials in Zambia: Research Findings | Dose Per Container Partnership (DPCP), JSI Research & Training Institute, Inc | 2019 | Case study | Anglais |
| The switch from ROTARIX to ROTAVAC in Ghana: Answers to four key questions | PATH | 2022 | Report | Anglais |
| Economic Implications of Switching Rotavirus Vaccine Products in Palestine's Immunization Program | PATH | 2020 | Case study | Russe |
| The Health Benefits of Rotavirus Immunization for Children in Palestine: Results of a Vaccine Impact Analysis | PATH, Rostropovich-Vishnevskaya Foundation, Palestine Ministry of Health | 2021 | Report | Russe |
